China Resources Double-Crane Pharmaceutical (SHA:600062) said its pentazocine injection passed the generic drug quality and efficacy consistency evaluation.
The notice was issued by the National Medical Products Administration, according to a Dec. 31 filing with the Shanghai bourse.
Pentazocine is used to treat severe chronic pain and serves as a pre-anesthetic as an auxiliary drug for surgical anesthesia.